SCHEMBL23799245

SCHEMBL23799245

CCOC(=O)N1CCCN(C2CCC(C)(c3ccccc3)CC2)CC1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.48
MAPK1 P28482 1/20 0.47
KDM4E B2RXH2 3/20 0.46
ALDH1A1 P00352 3/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
LMNA P02545 1/20 0.46
HTT P42858 1/20 0.46
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
OPRL1 P41146 1/20 0.45
CHRM1 P11229 3/20 0.45
HRH3 Q9Y5N1 1/20 0.45
GAA P10253 2/20 0.45
ALOX12 P18054 1/20 0.45
TP53 P04637 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
CHRM2 P08172 1/20 0.44
CHRM4 P08173 1/20 0.44
CHRM5 P08912 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20066008 0.87 CYP2D6 (0.48) POLBMAPK1KDM4EALDH1A1SMN1; SMN2
SCHEMBL20073973 0.86 POLB (0.48) POLBMAPK1KDM4EALDH1A1SMN1; SMN2
SCHEMBL20066038 0.85 HSD11B1 (0.48) POLBMAPK1KDM4ESMN1; SMN2LMNA
SCHEMBL20066073 0.85 CYP2D6 (0.49) POLBMAPK1KDM4EALDH1A1LMNA
SCHEMBL24609048 0.83 MEN1 (0.49) POLBMAPK1KDM4EALDH1A1SMN1; SMN2
SCHEMBL23798655 0.82 MAPK1 (0.43) POLBMAPK1KDM4EALDH1A1SMN1; SMN2
SCHEMBL20066015 0.80 GAA (0.46) POLBMAPK1KDM4EALDH1A1SMN1; SMN2
SCHEMBL20066013 0.79 POLB (0.48) POLBMAPK1SMN1; SMN2MEN1KMT2A
SCHEMBL20066007 0.78 HRH3 (0.51) KDM4EALDH1A1LMNAMEN1KMT2A
SCHEMBL20066010 0.78 MEN1 (0.51) MAPK1KDM4EALDH1A1SMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3526207-B1 HETEROCYCLIC COMPOUNDS HAVING ACTIVITY AS MODULATORS OF MUSCARINIC M1 AND/OR M4 RECEPTORS IN THE TREATMENT OF CNS DISEASES AND PAINS. HEPTARES THERAPEUTICS LTD (GB) 2021-09-08 EP disclosed